2021 – Onxeo

Onxeo Announces its Financial Agenda for 2022

01/13/2022

Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]

Onxeo appoints Julien Miara as new interim CEO

01/03/202201/03/2022

Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]

New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments

12/08/202112/08/2021

These pioneering data were highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions Paris (France), December 8, 2021 […]

Onxeo Continues to Strengthen its Board of Directors

11/23/202111/23/2021

Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member Paris […]

Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector

10/14/202110/14/2021

Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]

Onxeo Reports its 2021 Half-Yearly Financial Results and Provides an Update on its Activities

07/29/202107/29/2021

Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]

Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board

07/29/202107/29/2021

Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee […]

Kepler Cheuvreux Digital Life Sciences Day

By invitation only For more information, visit : www.keplercheuvreux.com Download management presentation

Onxeo: Report on the Combined General Meeting of June 10, 2021

06/10/2021

All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

06/09/2021

This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]

Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts

05/31/202105/28/2021

This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]

H.C. Wainwright 23rd Annual Global Investment Conference

Hybrid Conference In-Person Location – New York City Click here for more information and to register

Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information

05/21/202105/21/2021

Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

BIO Digital 2021

Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership. Click here to register To set up virtual meetings with […]

Onxeo announces the success of its Rights Issue with €9.7 million raised

04/12/202105/21/2021

This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]

Onxeo Launches a Rights Issue to accelerate its R&D programs

03/10/202105/21/2021

This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]

Publication of the 2020 Annual Financial Report

04/23/2021

Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

Annual Financial Results 2020

The management will comment the financial results and provide an update on the Company’s activities and perspectives through a video […]

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update

04/21/2021

Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]

Combined Annual Shareholders’ Meeting

More information coming soon

MEET2WIN – European Oncology Partnering Convention

For more information, visit the MEET2WIN Convention website To meet with us during the Convention, please contact bd@onxeo.com

Onxeo to Present New Preclinical Data at AACR 2021

04/08/202104/08/2021

Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]

B-Smart – Interview of Judith Greciet, CEO of Onxeo

03/26/2021

Watch the interview (in French)

Onxeo will publish its annual results on April 21, 2021

03/24/2021

The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]

ESMO Targeted Anticancer Therapies Congress 2021

Watch the e-poster “AsiDNA™ targets drug-tolerant persister cells responsible of resistance to PARP inhibitors”

4th Annual PARP & DDR Inhibitors Summit

For more information Download the presentation “AsiDNA™ and PARP inhibitors: Drug-driven synthetic lethality and beyond” Watch the video of […]

Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children

02/04/202102/04/2021

This study is supported by a grant from the European Fight Kids Cancer program[1] Paris (France), February 4, 2021 […]